Rabbit anti Human SPARC

Nordic MuBio
Product Code: EXA-X1867P
Product Group: Primary Antibodies
Supplier: Nordic MuBio
CodeSizePrice
EXA-X1867P70 ug£442.00
Quantity:
Prices exclude any Taxes / VAT

Overview

Host Type: Rabbit
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Human
Applications:
  • Enzyme-Linked Immunosorbent Assay (ELISA)
  • Immunohistochemistry (IHC)
  • Western Blot (WB)
Shipping:
Ship on dry ice freeze upon arrival
Storage:
Product should be stored at -70°C. Aliquot to avoid freeze/thaw cycles

Further Information

Applications Description:
Antibody can be used for Western blotting (0.5-1 ?g/ml). Optimal concentration should be evaluated by serial dilutions.
Background:
SPARC is a key factor in cell-matrix interactions and possibly tumour aggressiveness. The SPARC gene, which encodes a multifunctional glycoprotein with roles in tissue development, remodelling and fibrosis. A regulator of cell-extracellular matrix (ECM) interactions, SPARC represents a major factor in the ECM remodelling occurring during tumour invasion. in silico analysis reveals 4 UTR-SNPs located in the 3 -UTR of the SPARC gene, corresponding to 1474 g a, 1551 g c, 1922 t g and 2072 c t changes, which are significantly associated with tumoral state of the tissue. Of all hits, the 2072 SPARC polymorphism had the best association with cancer. SPARC therefore is a gene involved in a number of diseases including rheumatoid arthritis, scleroderma, tumor development and metastasis. SPARC variants have been detected in tumour samples of patients with acute myeloblastic leukemia (AML).
Caution:
This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving humans or animals.
Concentration:
Lot specific, see vial
Field of Interest:
Signal Transduction
Formulation:
Provided as ligand affinity purified antibody in phosphate buffered saline with 0.08% sodium azide
Functional Analysis:
Western Blotting, IHC
Immunogen:
Synthetic peptide derived from the human SPARC protein.
Positive Control:
Antibody has been tested on mouse heart lysate.
Product Form:
Affinity Purified
Product Stability:
Products are stable for one year from purchase when stored properly
Purification Method:
Antigen Immunoaffiinity Purification
Synonyms:
Secreted Protein Acidic and Rich in Cysteine, SPARC, SPARC-related modular calcium-binding protein 2 [Precursor], Secreted modular calcium-binding protein 2, SMOC-2, Smooth muscle-associated protein 2, SMAP-2
UniProt:
P09486

References

1. Shi Q, et al. 'Targeting SPARC expression decreases glioma cellular survival and invasion associated with reduced activities of FAK and ILK kinases.' Oncogene. 2007 Jan 8; [Epub ahead of print] PMID: 17213807

2. Aouacheria A, et al. 'In silico whole-genome screening for cancer-related single-nucleotide polymorphisms located in human mRNA untranslated regions.' BMC Genomics. 2007 Jan 3;8(1):2 [Epub ahead of print] PMID: 17201911

3. Xue LY, et al. 'Tissue microarray analysis reveals a tight correlation between protein expression pattern and progression of esophageal squamous cell carcinoma.'
BMC Cancer. 2006 Dec 22;6(1):296 [Epub ahead of print] PMID: 17187659

4. Arp HP, et al. 'Predicting the partitioning behavior of various highly fluorinated compounds.' Environ Sci Technol. 2006 Dec 1;40(23):7298-304. PMID: 17180981

5. Kelly KA, et al. 'SPARC is a VCAM-1 counter-ligand that mediates leukocyte transmigration.' J Leukoc Biol. 2006 Dec 18; [Epub ahead of print]

6. Markovic, S., et al. 'Tumor SPARC microenvironment signature (SMS) and plasma levels in a phase II trial of unresectable stage IV melanoma treated with nab-paclitaxel and carboplatin: A translational study of NCCTG trial N057E.' J. Clin. Oncol. 2010, Vol. 28, No. 15, 8578

7. Weiss, G.J., et al. 'Molecular characterization of interdigitating dendritic cell sarcoma.' Rare Tumors, 2010, 2:e50

8. Alonso, E.N., et al. ?Genes Related to Suppression of Malignant Phenotype Induced by Maitake D-Fraction in Breast Cancer Cells.? J. Med. Food., 16, 602-617 (2013).